Skip to main content

Aclaris Therapeutics, Inc.

corporate_fare Company Profile

Aclaris Therapeutics, Inc.

ACRS·NASDAQ·Life Sciences·CIK 0001557746

We are a clinical-stage biopharmaceutical company focused on discovering and developing novel small and large molecule product candidates for immuno-inflammatory diseases. Our proprietary KINect drug discovery platform, combined with our integrated discovery approach for small and large molecules, allows us to identify and advance product candidates designed for superior target affinity, specificity, and potency. We aim to identify and complete transactions with third-party partners to further develop, obtain marketing approval for, and/or commercialize our novel product candidates. We are dedicated to developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. Our approach includes leveraging our discovery, research, and development expertise, which encompasses state-of-the-art capabilities in small molecule and antibody development, including cell and molecular biology, biochemistry, enzymology, biomarker development, immunology, translational research, in vivo efficacy models, structure-based drug design ("SBDD"), and bioanalytical, computational, and medicinal chemistry. Our team also has broad experience in clinical development and strategy across atopic, respiratory, inflammatory, and immunologic diseases. We also develop innovative biologic product candidates targeting validated pathways, advancing biologics programs comprising monoclonal and multispecific antibodies targeting well-characterized pathways in immuno-inflammatory diseases. Our biologics pipeline includes bosakitug (ATI-045), an anti-thymic stromal lymphopoietin ("TSLP") monoclonal antibody, which has unique differentiation demonstrated by its low dissociation rate, long residence time, and high potency. TSLP is a master regulator of type 2 ("Th2") immune responses and a broadly active key mediator in various inflammatory conditions.

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for ACRS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for ACRS spans 8-K, 10-Q, 424B5, S-3ASR.

Recent high-impact activity:

  • Aclaris' Bosakitug Misses Phase 2 ADMIRATION Endpoint; Pivots to Oral Kinase and ATI-052 Programs
  • Phase 2 Atopic Dermatitis Trial Fails; Aclaris Pivots to ITK Inhibitors and ATI-052
  • Aclaris Q3 10-Q: $204.6M Cash, $59.8M Nine-Month Loss, $116M Raised Via ATM
  • Aclaris Q3 2026: $204.6M Cash, Runway to 1H 2029, ATI-052 Pivots to EoE
  • Aclaris Prices $50M Offering at $3.50, a 7.7% Discount to Last Sale, Alongside Positive ATI-052 Data

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$7.83M
Net Income
-$64.92M
Diluted EPS
-$0.53
Op. Cash Flow
-$47.11M
Free Cash Flow
-$47.22M
Gross Profit
$5.74M
Operating Income
-$76.38M
Cash & Equivalents
$19.96M
Debt / Equity
0.00×
Net Margin
-8.30×
Shares Outstanding
120.5M sh
Source: 10-K · filed 2026-02-26 · accession 0001104659-26-020540

Short Interest & Short Volume

4.02 days to cover

FINRA reported short interest of 11,572,867 shares in ACRS as of the October 30, 2026 settlement, a 23.0% decrease from the prior period — about 4.0 days to cover at its recent average daily volume. On November 20, 2026, 68.4% of ACRS volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)11,572,867 shares as of October 30, 2026
Change vs prior period▼ 23.0%
Days to cover4.02 at avg daily volume of 2,876,959
Daily short volume (FINRA facilities)68.4% of 618,920 shares on November 20, 2026
5-day average short volume48.0%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for ACRS, detected from its recent SEC filings · based on capital-structure filings through 2026-10-27.

1 recent capital raiseATM program1 shelf registration

Priced $50M Underwritten Offering · Net Proceeds and Fees

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with A →
$3.44
52-week range · as of 2026-11-16 $2.25 – $6.6
Market cap
$545.63M
Volume
2.2M (0.8× avg)
3-mo avg 2.8M
Live data · 2026-11-22 12:40 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ACRS - Latest Insights

ACRS
Nov 16, 2026, 6:03 AM EST
Filing Type: 8-K
Importance Score:
8
Updated Nov 16, 9:58 AM ET — Aclaris shares fell 8.7% to $3.58 after the bosakitug Phase 2 atopic dermatitis failure.
Price at Filing: $3.28
Real-time Price: $3.44 info
Change: +$0.160 (+5%) info
Market Cap: $545.626M info
ACRS
Nov 16, 2026, 3:28 AM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.76
Real-time Price: $3.44 info
Change: -$0.320 (-9%) info
Market Cap: $545.626M info
ACRS
Nov 05, 2026, 4:30 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $3.61
Real-time Price: $3.44 info
Change: -$0.170 (-5%) info
Market Cap: $545.626M info
ACRS
Nov 05, 2026, 7:15 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.61
Real-time Price: $3.44 info
Change: -$0.170 (-5%) info
Market Cap: $545.626M info
ACRS
Oct 27, 2026, 5:15 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $3.72
Real-time Price: $3.44 info
Change: -$0.280 (-8%) info
Market Cap: $545.626M info
ACRS
Oct 27, 2026, 6:43 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.63
Real-time Price: $3.44 info
Change: -$0.190 (-5%) info
Market Cap: $545.626M info
ACRS
Oct 27, 2026, 6:06 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.03
Real-time Price: $3.44 info
Change: -$0.590 (-15%) info
Market Cap: $545.626M info
ACRS
Oct 27, 2026, 6:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $4.03
Real-time Price: $3.44 info
Change: -$0.590 (-15%) info
Market Cap: $545.626M info
ACRS
Aug 06, 2026, 5:08 PM EDT
Filing Type: S-3ASR
Importance Score:
7
Price at Filing: $6.10
Real-time Price: $3.44 info
Change: -$2.66 (-44%) info
Market Cap: $545.626M info
ACRS
Aug 06, 2026, 4:35 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $6.34
Real-time Price: $3.44 info
Change: -$2.90 (-46%) info
Market Cap: $545.626M info
ACRS
Aug 06, 2026, 7:15 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.11
Real-time Price: $3.44 info
Change: -$2.67 (-44%) info
Market Cap: $545.626M info
ACRS
May 07, 2026, 4:32 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $4.86
Real-time Price: $3.44 info
Change: -$1.42 (-29%) info
Market Cap: $545.626M info
ACRS
May 07, 2026, 7:15 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.80
Real-time Price: $3.44 info
Change: -$1.36 (-28%) info
Market Cap: $545.626M info
ACRS
May 07, 2026, 6:59 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $4.80
Real-time Price: $3.44 info
Change: -$1.36 (-28%) info
Market Cap: $545.626M info
ACRS
Apr 28, 2026, 6:45 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $4.72
Real-time Price: $3.44 info
Change: -$1.28 (-27%) info
Market Cap: $545.626M info
ACRS
Apr 28, 2026, 6:32 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $4.73
Real-time Price: $3.44 info
Change: -$1.29 (-27%) info
Market Cap: $545.626M info
ACRS
Mar 27, 2026, 10:10 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.53
Real-time Price: $3.44 info
Change: -$0.085 (-2%) info
Market Cap: $545.626M info
ACRS
Mar 11, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.67
Real-time Price: $3.44 info
Change: -$0.2336 (-6%) info
Market Cap: $545.626M info
ACRS
Mar 10, 2026, 6:13 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $3.43
Real-time Price: $3.44 info
Change: +$0.0100 (+0.29%) info
Market Cap: $545.626M info
ACRS
Feb 26, 2026, 4:31 PM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $3.13
Real-time Price: $3.44 info
Change: +$0.310 (+10%) info
Market Cap: $545.626M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets